Printed From BioPortfolio.com
Cullinan Oncology Emerges with $150M to Build Cancer Drug Portfolio
00:01 EDT 3 Oct 2017 | Xconomy
It’s no secret that discovering and developing cancer drugs is an expensive and risky endeavor. But Cullinan Oncology is betting that a financial approach, rather than a purely scientific one, can improve the odds, and it has raised $150 million to test its approach. The Series A investment for Cambridge, MA-based Cullinan was co-led by […]
Original Article: Cullinan Oncology Emerges with $150M to Build Cancer Drug Portfolio
